Celsius Therapeutics is a clinical-stage biotechnology company developing novel precision medicines in inflammatory disease by harnessing the power of single cell RNA sequencing and human biology at scale. The company’s first therapeutic candidate is an anti-TREM1 antibody for the treatment of IBD. Celsius is based in Cambridge, Mass.